TrialBridge

NCT07564752

The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes

Recruiting · Not specified · Centre Hospitalier Universitaire Dijon · registry updated 2026-05-04

Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.

The HAGI-T1D study aims to determine the effect of improved glycemic control on the composition and function of high-density lipoproteins (HDL) in patients with type 1 diabetes (T1D). It requires the establishment of a biological plasma/serum bank. T1D patients hospitalized in the Endocrinology-Diabetology-Metabolic Diseases Department at the Dijon Bourgogne University Hospital for poorly controlled diabetes (defined by glycated hemoglobin HbA1c \>8.0%). The study includes a T1D group of 80 patients with unsatisfactory glycemic control, who will undergo intensified therapy in accordance with standard clinical practice (modification of insulin therapy, therapeutic education, and lifestyle and dietary guidelines). The study also includes a control group of 63 non-diabetic, non-dyslipidemic subjects enrolled based on the results of laboratory tests from the screening visit to assess whether improved glycemic control in the T1D group restores anti-atherogenic functions and HDL composition to a level comparable to that of the control group.

Inclusion

  • Control group non-diabetic and non-dyslipidemic :
  • A person who has giver written consent
  • Fasting blood glucose \< 1,10 g/L
  • Triglycerides \< 1,50 g/L (\< 1,70 mmol/L).
  • HDL cholesterol \> 1,03 mmol/L (men) or \> 1,30 mmol/L (women).
  • LDL cholesterol \< 1,60 g/L.

Exclusion

  • All participants :
  • A person who is not enrolled in or eligible for a social security program
  • A person subject to a legal protective measure (guardianship, tutorship)
  • A person subject to a judicial protective measure
  • Pregnant women, women in labor, or breastfeeding women
  • Adults who are legally incompetent or unable to give informed consent

Open NCT07564752 on ClinicalTrials.govAll conditions